Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment

BACKGROUND: Natalizumab (NTZ) and ocrelizumab (OCR) can be used for the treatment of relapsing–remitting multiple sclerosis (RRMS). In patients treated with NTZ, screening for JC virus (JCV) is mandatory, and a positive serology usually requires a change in treatment after 2 years. In this study, JC...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Vendrell, Albert, Arroyo-Pereiro, Pablo, León, Isabel, Bau, Laura, Matas, Elisabet, Martínez-Yélamos, Antonio, Martínez-Yélamos, Sergio, Romero-Pinel, Lucía
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129953/
https://www.ncbi.nlm.nih.gov/pubmed/36913038
http://dx.doi.org/10.1007/s00415-023-11645-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129953/
https://www.ncbi.nlm.nih.gov/pubmed/36913038
http://dx.doi.org/10.1007/s00415-023-11645-x

Ejemplares similares